BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mayne Pharma (AU:FHF) Announces Addition Of Fluconazole Injection Mini Bags To Its Product Line


10/19/2005 5:11:20 PM

PARAMUS, N.J., July 30 /PRNewswire/ -- Mayne Pharma (USA) Inc. announces that the US Food and Drug Administration (FDA) has granted approval for the company's Abbreviated New Drug Application for Fluconazole Injection mini bags.

Stuart Hinchen, Mayne Pharma's President of the America's said, "Adding Fluconazole to our growing list of products is a very exciting step for Mayne. It builds on our hospital offering, increases the therapeutic categories in which we offer products from pain management, cancer, hypertension and heart disease to now also include anti-infectives, as well as demonstrating our capacity to now offer products in mini-bags." Additionally, Mr. Hinchen noted that "for increased patient safety all our Fluconazole presentations are unit- of-use bar-coded, a feature that we have on all our products."

Fluconazole is used for the treatment of systemic fungal infections. Mayne Pharma will be making Fluconazole Injection (2mg/mL) in 0.9% Sodium Chloride injection available in 10 packs of 200 mg/100 mL and 400 mg/200 mL mini bags.

Mayne Group Limited, the parent of Mayne Pharma (USA) Inc. has businesses in pharmaceuticals (the manufacture of oral and injectable pharmaceuticals for distribution to more than 50 countries) as well as Australian-based businesses in diagnostic services (pathology, diagnostic imaging and medical centres), pharmacy and health-related consumer products.

Mayne Pharma (USA) Inc.

CONTACT: Joe Marchese, VP Sales and Marketing, +1-201-225-5572, forMayne Pharma (USA) Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES